comparemela.com

Latest Breaking News On - Westlake biopartners - Page 2 : comparemela.com

Exclusive: What Andreessen Horowitz s Anish Acharya is looking for in consumer AI startups

At Davos, Sam Altman is a headliner, with star status scrutiny to match

Sam Altman is a leading voice at Davos, which means he’s sounding off on everything from elections to energy. It also means he’s more watched than ever.

Westlake Village BioPartners Names Peter Calveley as Chief Operating Officer

Press release content from PR Newswire. The AP news staff was not involved in its creation. Westlake Village BioPartners Names Peter Calveley as Chief Operating Officer February 17, 2021 GMT (PRNewsfoto/Westlake Village BioPartners) LOS ANGELES, Feb. 17, 2021 /PRNewswire/ Westlake Village BioPartners today announced the appointment of Peter Calveley to the position of Chief Operating Officer. Mr. Calveley will be responsible for managing the operational side of the firm, as well as enhancing strategic decision-making for Westlake’s portfolio of life sciences companies. Prior to joining Westlake, Mr. Calveley was a Managing Director in the Investment Banking Group at SVB Leerink based out of San Francisco and was responsible for companies in the biotech sector in the Western U.S. and Canada.

Westlake Village BioPartners Launches Two Funds Totaling $500M

Westlake Village BioPartners Launches Two Funds Totaling $500M Westlake Village BioPartners has launched two new funds totaling $500m.  The new vehicles will enable the firm to build and invest in promising life sciences companies with transformative human therapeutic technologies. The first fund, known as Opportunity 1, is $70m and allows Westlake to invest additional Series B or later-round capital into promising companies they incubated or invested in with their original fund, Westlake BioPartners 1 (WBP1). The second fund, Westlake Village BioPartners 2 Fund (WBP2), is $430m and will focus on incubating and investing in approximately 12 Series A startups or co-lead Series A rounds with other investors, and will also allow for additional Series B or later-round investments in the most promising of these companies.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.